Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence

NCT02447679 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Adult Hepatocellular Carcinoma
Recurrent Hepatocellular Carcinoma
Adverse Reaction to Drug
Vascular Endothelial Growth Factor Overexpression

Interventions

DRUG: thalidomine
DRUG: tegafur-uracil

Sponsor

Chang Gung Memorial Hospital